Karsten Damgaard-Iversen (Chairman) is an internationally accomplished business professional with 30+ years of global experience working in the healthcare imaging industry. He is a proven leader with a successful track record in operational and strategic management positions within small, medium and large medical imaging and healthcare technology companies. Mr. Damgaard-Iversen combines strong business acumen with in-depth technical and medical knowledge and has served in executive positions such as Managing Director and Chief Group Executive of Toshiba Medical Systems Europe BV, Managing Director of Toshiba Medical Systems (UK) Ltd., Vice President of International Operations of Fisher Imaging Corporation and Director of Sales & Marketing of Storz Medical AG. Mr. Damgaard-Iversen has also been a direct contributor to the invention and development of specific laser and x-ray based medical products. He holds an MBA from Emory University and a BSc in electronic engineering from Copenhagen University College.

Prof. Sir Michael Brady FRS, FREng is BP Professor of Information Engineering at the University of Oxford. He combines his work at Oxford University, where he founded the Robotics Laboratory and the Medical Vision Laboratory (MVL), with a range of entrepreneurial activities. He is a non-executive director of AEA Technology and Isis Innovation (Oxford University's intellectual property company) and was also a founding director of successful start-up companies such as Guidance and, of course, Mirada Medical. He is a Fellow of the Institution of Electrical Engineers and a founding Fellow of the Association of Artificial Intelligence. He is also a Fellow of the Institute of Physics, and a Fellow of the British Computing Society. He was awarded the IEE Faraday Medal in 2000 and also the IEEE Third Millennium Medal for the UK. In 2005 the Royal Institution awarded Professor Sir Michael Brady the Henry Dale Prize for "outstanding work on a biological topic by means of an original multidisciplinary approach".

Dr Christian Behrenbruch is an experienced entrepreneur with a decade of experience in starting and financing early-stage technology companies, largely based on technology developed in the university setting. He is currently CEO of ImaginAb, Inc. an LA-located biotechnology company that was launched based on technology developed at the University of California Los Angeles (UCLA). Directly or indirectly, he has been responsible for starting around 20 early stage companies in the medtech, life sciences and materials/nanotechnology domain and maintains an active interest in the challenges of taking new ideas out of the university setting and into the market— particularly in regulated areas like healthcare. Dr Behrenbruch is active in the university setting and has held academic appointments and taught at institutions such as UCLA, Caltech, Zhejiang University (Hangzhou, China), ESMT (Berlin) and Oxford University. He holds a Bachelor of Engineering from Monash University, a PhD (D.Phil) from the University of Oxford and an MBA jointly issued by NYU Stern School of Business and the London School of Economics.

Mark Evans FCA MCT MBA is a Chartered Accountant (UK equivalent to a CPA), a qualified Corporate Treasurer and holds an MBA from Saïd Business School, Oxford University. Mark’s experience runs from technology start-ups to being a CFO responsible for a EUR 800m business within a multi-national corporation. Mark’s experience in medical technology includes being European Finance Director for CTI Molecular Imaging; COO then MD of Mirada Solutions Ltd, a medical imaging software company; MD of PETNET Solutions in the UK, a radiopharmaceutical production company; and Vice President and European CFO of a 26 market region of Siemens Diagnostics.

David Gudgin qualified as a management accountant with ICL before spending 3 years at the BBC. In 1999 he joined 3i as an investor in European technology based in London and Amsterdam. In 2002 he moved to Foursome Investments (now Frog Capital) as the lead investor of two funds, an environmental technology fund and a later stage development capital fund. David joined Close Ventures in 2005 and became a partner in Albion Ventures in 2009. David has a Bsc in Economics from Warwick University.